- Home
- IMNM vs QURE Comparison
IMNM vs QURE Comparison
Compare IMNM & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- QURE
- Stock Information
- Founded
- IMNM 2006
- QURE 1998
- Country
- IMNM United States
- QURE Netherlands
- Employees
- IMNM N/A
- QURE N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- QURE Health Care
- Exchange
- IMNM Nasdaq
- QURE Nasdaq
- Market Cap
- IMNM 748.3M
- QURE 725.4M
- IPO Year
- IMNM 2020
- QURE 2007
- Fundamental
- Price
- IMNM $8.84
- QURE $14.42
- Analyst Decision
- IMNM Strong Buy
- QURE Strong Buy
- Analyst Count
- IMNM 5
- QURE 10
- Target Price
- IMNM $26.40
- QURE $37.20
- AVG Volume (30 Days)
- IMNM 1.0M
- QURE 1.2M
- Earning Date
- IMNM 08-11-2025
- QURE 07-31-2025
- Dividend Yield
- IMNM N/A
- QURE N/A
- EPS Growth
- IMNM N/A
- QURE N/A
- EPS
- IMNM N/A
- QURE N/A
- Revenue
- IMNM $10,938,000.00
- QURE $20,201,000.00
- Revenue This Year
- IMNM N/A
- QURE N/A
- Revenue Next Year
- IMNM $310.65
- QURE $278.91
- P/E Ratio
- IMNM N/A
- QURE N/A
- Revenue Growth
- IMNM N/A
- QURE 6.30
- 52 Week Low
- IMNM $5.15
- QURE $3.73
- 52 Week High
- IMNM $16.81
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- IMNM 50.27
- QURE 48.56
- Support Level
- IMNM $8.35
- QURE $13.65
- Resistance Level
- IMNM $9.34
- QURE $14.75
- Average True Range (ATR)
- IMNM 0.53
- QURE 0.76
- MACD
- IMNM -0.07
- QURE -0.14
- Stochastic Oscillator
- IMNM 33.97
- QURE 36.55
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.